NR4A1 and breast carcinoma: Methods: Patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) who had no prior chemoradiotherapy (ET) and 1 prior line of chemotherapy for advanced disease were administered RIB + LET.